Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies-Reference-Cited by-同舟云学术

Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies

Published:2023-10-13 Issue:41 Volume:9 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Zendt Mackenzie¹^ORCID,Bustos Carrillo Fausto A.¹²^ORCID,Kelly Sophie³^ORCID,Saturday Taylor⁴,DeGrange Maureen¹⁵^ORCID,Ginigeme Anita¹⁶^ORCID,Wu Lurline¹,Callier Viviane⁷,Ortega-Villa Ana⁸^ORCID,Faust Mondreakest⁹,Chang-Rabley Emma¹^ORCID,Bugal Kara¹⁰,Kenney Heather¹,Khil Pavel¹⁰^ORCID,Youn Jung-Ho¹⁰,Osei Gloria¹⁰,Regmi Pravesh¹⁰,Anderson Victoria¹,Bosticardo Marita¹^ORCID,Daub Janine¹,DiMaggio Thomas¹^ORCID,Kreuzburg Samantha¹,Pala Francesca¹^ORCID,Pfister Justina¹^ORCID,Treat Jennifer¹,Ulrick Jean¹,Karkanitsa Maria⁹^ORCID,Kalish Heather³^ORCID,Kuhns Douglas B.⁵^ORCID,Priel Debra L.⁵^ORCID,Fink Danielle L.⁵,Tsang John S.¹¹¹²^ORCID,Sparks Rachel¹³^ORCID,Uzel Gulbu¹,Waldman Meryl A.¹⁴^ORCID,Zerbe Christa S.¹^ORCID,Delmonte Ottavia M.¹^ORCID,Bergerson Jenna R. E.¹,Das Sanchita¹⁰^ORCID,Freeman Alexandra F.¹^ORCID,Lionakis Michail S.¹^ORCID,Sadtler Kaitlyn⁹^ORCID,van Doremalen Neeltje⁴^ORCID,Munster Vincent⁴^ORCID,Notarangelo Luigi D.¹^ORCID,Holland Steven M.¹^ORCID,Ricotta Emily E.¹^ORCID

Affiliation:

1. Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research (DIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.

2. Office of Data Science and Emerging Technologies, Office of Science Management and Operations, NIAID, NIH, Rockville, MD, USA.

3. Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH, Bethesda, MD, USA.

4. Laboratory of Virology, DIR, NIAID, NIH, Hamilton, NY, USA.

5. Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

6. Medical Science and Computing LLC, Rockville, MD, USA.

7. Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

8. Biostatistics Research Branch, Division of Clinical Research, NIAID, NIH, Rockville, MD, USA.

9. Section for Immunoengineering, NIBIB, NIH, Bethesda, MD, USA.

10. Division of Laboratory Medicine, NIH Clinical Center, Bethesda, MD,USA.

11. Department of Immunobiology and Yale Center for Systems and Engineering Immunology, Yale School of Medicine, New Haven, CT, USA.

12. Department of Biomedical Engineering, Yale University, New Haven, CT,USA.

13. Laboratory of Immune System Biology, DIR, NIAID, NIH, Bethesda, MD,USA.

14. Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.

Abstract

Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people (IDP) has focused on cancer and organ transplantation populations. In a prospective cohort of 195 IDP and 35 healthy volunteers (HV), antispike immunoglobulin G (IgG) was detected in 88% of IDP after dose 2, increasing to 93% by 6 months after dose 3. Despite high seroconversion, median IgG levels for IDP never surpassed one-third that of HV. IgG binding to Omicron BA.1 was lowest among variants. Angiotensin-converting enzyme 2 pseudo-neutralization only modestly correlated with antispike IgG concentration. IgG levels were not significantly altered by receipt of different messenger RNA–based vaccines, immunomodulating treatments, and prior severe acute respiratory syndrome coronavirus 2 infections. While our data show that three doses of coronavirus disease 2019 vaccinations induce antispike IgG in most IDP, additional doses are needed to increase protection. Because of the notably reduced IgG response to Omicron BA.1, the efficacy of additional vaccinations, including bivalent vaccines, should be studied in this population.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Link

https://www.science.org/doi/pdf/10.1126/sciadv.adh3150

Reference67 articles.

1. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

2. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study

3. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

4. The Risk and Impact of COVID-19 Pandemic on Immunosuppressed Patients: Cancer, HIV, and Solid Organ Transplant Recipients

5. Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor?

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Improvement of Adaptive Immune Responses towards COVID-19 Following Diphtheria–Tetanus–Pertussis and SARS-CoV-2 Vaccinations in Indonesian Children: Exploring the Roles of Heterologous Immunity;Vaccines;2024-09-09

2. Stuck in pandemic uncertainty: a review of the persistent effects of COVID-19 infection in immune-deficient people;Clinical Microbiology and Infection;2024-08

3. An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity;Vaccines;2024-06-18

4. Impact of Exposure to Vaccination and Infection on Cellular and Antibody Response to SARS-CoV-2 in CVID Patients Through COVID-19 Pandemic;Journal of Clinical Immunology;2023-12-22

5. Effects of Oregano Essential Oil on IgA+, IgG+, and IgM+ Cells in the Jejunum of Castrated Holstein Bulls;Animals;2023-12-06